An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

NCT ID: NCT00109057

Last Updated: 2013-06-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-02-28
• Study Completion Date: 2004-02-29

Brief Summary

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not show evidence of disease progression at completion of the parent study will be eligible for inclusion in this trial.

Conditions

Cancer

Study Design

• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Avastin (bevacizumab)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Previous participation in and completion of a Genentech-sponsored rhuMAb VEGF Phase I or Phase II cancer study
• No evidence of progressive disease at completion of the parent study
• For women of childbearing potential, use of an effective means of contraception
• Signed informed consent

Exclusion Criteria

• Any unresolved or irreversible rhuMAb VEGF-related ongoing serious adverse events occurring during the parent study
• Any history of central nervous system disease (e.g., primary brain tumor or seizures within 12 months of the first infusion on this study), and/or any evidence of brain metastases
• Compromised renal or hepatic function, as defined in the parent protocol
• Anemia, neutropenia, or thrombocytopenia, as defined in the parent protocol
• Pregnancy (positive pregnancy test) or lactation
• Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored rhuMAb VEGF cancer study
• Recent (within 3 weeks of the first infusion of this study) major surgical procedure, biopsy of a parenchymal organ, or significant traumatic injury
• Clinically significant cardiovascular disease (e.g., uncontrolled hypertension [blood pressure of >160/110 mmHg on medication], myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac dysrhythmia requiring medication, or peripheral vascular disease (Grade II or greater)
• Serious, nonhealing wound, ulcer, or bone fracture
• Current or recent (within 10 days of the first infusion on this study) use of oral or parenteral anticoagulants or aspirin (except as required to maintain patency of permanent indwelling intravenous [IV] catheters)
• Inability to comply with study and/or follow-up procedures
• History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

AVF0778g

Identifier Type: -

Identifier Source: org_study_id